---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-23-000004"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T23:29:13.593473+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vertex reports FY22 product revenue $8.93B (+18% YoY); guides FY23 $9.55-$9.7B

## Summary
- Full year 2022 product revenue $8.93B, up 18% vs 2021; GAAP net income $3.32B, up 42%.
- Q4 product revenue $2.30B (+11% YoY); GAAP diluted EPS $3.15, non-GAAP $3.76.
- FY2023 product revenue guidance of $9.55B-$9.7B, implying 7-9% growth.
- Exa-cel regulatory submissions validated in EU and UK; US rolling BLA underway.
- CF drug TRIKAFTA/KAFTRIO generated $7.69B in FY22, up 35% from $5.70B in FY21.

## SEC filing metadata
- accession: 0000875320-23-000004
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/0000875320-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/vrtx-20230207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-23-000004
- JSON: https://secwatch.observer/filing/0000875320-23-000004.json
- Plain text: https://secwatch.observer/filing/0000875320-23-000004.txt

## Key facts
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA reported Three Months Ended December 31, 2022 results: revenue $ 2,303, net income $ 819, EPS $ 3.15. Guidance initiated.
  - Period: Three Months Ended December 31, 2022
  - Revenue: $ 2,303
  - Net income: $ 819
  - EPS: $ 3.15
  - Guidance: initiated
  - Result: reported results
  source text: Product revenues, net $ 2,303 $ 2,073 11% $ 8,931 $ 7,573 18% TRIKAFTA/KAFTRIO $ 2,022 $ 1,693 $ 7,687 $ 5,697 SYMDEKO/SYMKEVI $ 34 $ 80 $ 180 $ 420 ORKAMBI $ 111 $ 147 $ 511 $ 772 KALYDECO $ 136 $ 152 $ 553 $ 684 GAAP operating income $ 1,034 $ 878 18% $ 4,307 $ 2,782 55% Non-GAAP operating income* $ 1,150 $ 997 15% $ 4,793 $ 3,232 48% GAAP net income $ 819 $ 770 6% $ 3,322 $ 2,342 42% Non-GAAP net income* $ 978 $ 777 26% $ 3,855 $ 2,513 53% GAAP net income per share - diluted $ 3.15 $ 3.00 5% $ 12.82 $ 9.01 42%
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/0000875320-23-000004-index.htm
- Earnings Releases
  VERTEX PHARMACEUTICALS INC / MA reported Twelve Months Ended December 31, 2022 results: revenue $ 8,931, net income $ 3,322, EPS $ 12.82. Guidance initiated.
  - Period: Twelve Months Ended December 31, 2022
  - Revenue: $ 8,931
  - Net income: $ 3,322
  - EPS: $ 12.82
  - Guidance: initiated
  - Result: reported results
  source text: Product revenues, net $ 2,303 $ 2,073 11% $ 8,931 $ 7,573 18% TRIKAFTA/KAFTRIO $ 2,022 $ 1,693 $ 7,687 $ 5,697 SYMDEKO/SYMKEVI $ 34 $ 80 $ 180 $ 420 ORKAMBI $ 111 $ 147 $ 511 $ 772 KALYDECO $ 136 $ 152 $ 553 $ 684 GAAP operating income $ 1,034 $ 878 18% $ 4,307 $ 2,782 55% Non-GAAP operating income* $ 1,150 $ 997 15% $ 4,793 $ 3,232 48% GAAP net income $ 819 $ 770 6% $ 3,322 $ 2,342 42% Non-GAAP net income* $ 978 $ 777 26% $ 3,855 $ 2,513 53% GAAP net income per share - diluted $ 3.15 $ 3.00 5% $ 12.82 $ 9.01 42%
  evidence_url: https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/0000875320-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.